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This was a phase III trial
assessing whether reducing
radiation dose to uninvolved
bladder reduces toxicity
without impairing local
control; 219 patients were
randomized. No significant
differences in toxicity were
seen between standard and
reduced high-dose volume
RT groups. Rates of late
toxicity were lower than
anticipated. Noninferiority of
local control was not
formally proven. Radiation
therapy can be an effective
alternative to cystectomy in
patients with bladder cancer;
further study using image-
guided treatment with or
without dose escalation is
warranted.Purpose: To test whether reducing radiation dose to uninvolved bladder while maintaining dose
to the tumor would reduce side effects without impairing local control in the treatment of
muscle-invasive bladder cancer.
Methods and Materials: In this phase III multicenter trial, 219 patients were randomized to
standard whole-bladder radiation therapy (sRT) or reduced high-dose volume radiation therapy
(RHDVRT) that aimed to deliver full radiation dose to the tumor and 80% of maximum dose to
the uninvolved bladder. Participants were also randomly assigned to receive radiation therapy
alone or radiation therapy plus chemotherapy in a partial 2  2 factorial design. The primary
endpoints for the radiation therapy volume comparison were late toxicity and time to locoregio-
nal recurrence (with a noninferiority margin of 10% at 2 years).
Results: Overall incidence of late toxicity was less than predicted, with a cumulative 2-year
Radiation Therapy Oncology Group grade 3/4 toxicity rate of 13% (95% confidence interval
8%, 20%) and no statistically significant differences between groups. The difference in 2-year
locoregional recurrence free rate (RHDVRT  sRT) was 6.4% (95% confidence interval
7.3%, 16.8%) under an intention to treat analysis and 2.6% (12.8%, 14.6%) in the “per-
protocol” population.
Conclusions: In this study RHDVRT did not result in a statistically significant reduction in late
side effects compared with sRT, and noninferiority of locoregional control could not be
concluded formally. However, overall low rates of clinically significant toxicity combined with
low rates of invasive bladder cancer relapse confirm that (chemo)radiation therapy is a valid
option for the treatment of muscle-invasive bladder cancer.  2013 Elsevier Inc.Introduction
Muscle-invasive bladder cancer remains a major cause of cancer
death worldwide (1), with 5-year survival rates of <50% (2, 3).
Although cystectomy is frequently seen as standard treatment (4),
bladder-sparing protocols utilizing radical radiation therapy
are used as an alternative for those patients unsuitable for or
unwilling to undergo radical surgery. Historically, drawbacks of
this approach were twofold: (i) the rate of incomplete response
or local recurrence (up to 50%) (5) with the need for
subsequent salvage cystectomy; and (ii) the risk of late toxicity in
the bladder, rectum, or bowel (severe toxicity rates of 8%-10%,
3%-4%, and 1%-2% reported for bladder, rectum, and bowel,
respectively (6)).
When radiation therapy is used, difficulties in tumor localiza-
tion, in ensuring accuracy of treatment delivery, and the propen-
sity for bladder cancer to be multifocal have meant that the whole
bladder is conventionally taken as the target volume even if the
tumor appears localized. However, brachytherapy data (7) and
a small randomized trial (8) have suggested that targeting treat-
ment to the tumor may give equivalent local control, and retro-
spective data suggest that reducing normal bladder tissue included
in the high-dose volume may reduce the risk of toxicity (9).
A single-center pilot study of this approach resulted in lower
rates of toxicity (10); the radiation therapy volume comparison in
the BC2001 (CRUK/01/004) trial was designed to assess whether
this was reproducible across multiple centers without a detri-
mental effect on locoregional disease control. On the basis of
results of an earlier phase II study demonstrating safety of chemo-
radiation therapy (11), we also investigated whether outcomes can
be improved by the addition of chemotherapy to radiation therapy
(results reported separately (12)).Methods and Materials
Study design
BC2001 was a nonblinded phase III trial, with a partial 2  2
factorial design, conducted at 45 United Kingdom (UK) centers.
Patients with muscle-invasive bladder cancer providing written
informed consent were randomized (in a 1:1 ratio) to (i) standard
whole-bladder radiation therapy (sRT) or reduced high-dose
volume radiation therapy (RHDVRT) utilizing a tumor boost
and (ii) radiation therapy with or without synchronous chemo-
therapy (5-fluorouracil [5FU] and mitomycin C [MMC]).
Recruitment to the double randomization was encouraged but
optional according to patient eligibility and preference.
Independent randomization was via telephone to the Institute
of Cancer Research Clinical Trials and Statistics Unit (ICR-
CTSU). Computer-generated random permuted blocks were used,
stratifying by treating center, planned neoadjuvant chemotherapy
use, and entry to one or both randomizations.
Patient eligibility and selection
Eligible patients were aged 18 years with histologically
confirmed stage T2-T4aN0M0 bladder cancer (adenocarcinoma
or transitional or squamous cell carcinoma). Main inclusion
criteria were as follows: World Health Organization performance
status grade 0-2, leucocytes >4.0  109/L, platelets >100 
109/L, Glomerular filtration rate (GFR) >25 mL/min, and serum
bilirubin, Alanine transaminase (ALT), or Aspartate Trans-
aminase (AST) <1.5  upper limit of normal. Platinum-based
neoadjuvant chemotherapy was permitted but not mandatory.
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previous pelvic radiation therapy, bilateral hip replacements
likely to interfere with protocol treatment, pregnancy, and
inflammatory bowel disease.
Patients with multiple tumors at diagnosis were ineligible for
the radiation therapy volume randomization but could enter
the chemo-radiation therapy randomization; patients unsuitable
for chemotherapy could enter the radiation therapy volume
randomization.
Treatment
Two radiation therapy dose/fractionation schedules in standard use
in the UK were permitted: centers opted at study outset to use
either 55 Gy/20 fractions over 4 weeks or 64 Gy/32 fractions over
6.5 weeks for all participants. Patients allocated to concomitant
chemotherapy received 5FU (500 mg/m2/24 hours continuous
infusion during fractions 1-5 and 16-20 of radiation therapy
[10 days in total]) and MMC (12 mg/m2 intravenous bolus dose on
day 1).
Dose modifications for chemotherapy and radiation therapy
were permitted. In brief, the protocol recommended reducing or
omitting chemotherapy before interrupting radiation therapy to
minimize compromising delivery of “core” treatment.
Radiation therapy was CT planned with tumor, clinical, and
planning target volumes defined on 4 to 5 mm thick CT slices
taken at 4 to 5 mm intervals. Patients were CT planned with an
empty bladder and a rectum empty of flatus and feces. Target
outlining was performed according to local practice.
For patients allocated sRT (control) the planning target volume
(PTV) was the outer bladder wall plus the extravesical extent of
tumor with a 1.5 cm margin. An anterior and 2 lateral fields were
used to encompass the PTV in the 95% isodose. For RHDVRT
patients, 2 PTVs were defined: PTV1 as for the sRT group, and
PTV2 as gross tumor volume (ie, tumor seen on MRI/CT with
guidance of surgical bladder map) plus a 1.5-cm margin. Three-
dimensional conformal radiation therapy was used; RHDVRT
could be delivered as a concomitant boost. The aim of the
RHDVRT treatment was to deliver 100% (5%) of the reference
dose to PTV2 and 80% (5%) of the reference dose to PTV1
using 3 or 4 coplanar fields (Fig. e1, available online). Treatment
plans for the first patient treated with sRT and the first 2 patients
receiving RHDVRT at each site were centrally reviewed, with
structured feedback to the local investigator. In both groups,
nontarget normal tissues were excluded at the treating physician’s
discretion. Patients were set up according to bony landmarks. Soft
tissue matching was not used.
Trial assessments
At baseline all patients underwent physical examination, hema-
tologic, renal, and biochemical profile examination, bladder
capacity assessment, CT scan of abdomen and pelvis, chest x-ray
or CT, and examination under anesthetic plus cystoscopic resec-
tion of tumor and biopsy. The TNM classification (1997) was used
for staging (13).
Patients were seen weekly throughout treatment for toxicity
assessment using National Cancer Institute Common Toxicity
Criteria (CTC) (14). Side effects were then assessed at 6, 9, and 12
months after randomization and annually thereafter using the
Radiation Therapy Oncology Group (RTOG) (15) and Late Effectsof Normal Tissue (Subjective, Objective, Management) (LENT/
SOM) (16) scales. Bladder capacity was measured at 1 and 2 years
by urodynamic examination, cystoscopy, or ultrasound (same
technique used for individual patients).
Tumor control was assessed by physical examination, chest
x-ray, and rigid or flexible cystoscopy at 6, 9, and 12 months after
randomization and annually to 5 years. Biopsy of the tumor bed
and normal bladder was mandated at 6 months and repeated if
indicated at subsequent visits. Computed tomography scans of
the abdomen and pelvis were performed 1 and 2 years after
randomization and then as indicated.
Endpoints
Late radiation therapy related side effects (at 1 and 2 years) and
local control were the principal endpoints of interest. Late toxicity
was assessed by worst toxicity grade and change in bladder
capacity. Locoregional recurrenceefree (LRRF) survival was
defined as time from randomization to first recurrence in pelvic
nodes or bladder, censored at date of first metastasis (if 30
days before locoregional recurrence), second primary, or death or,
for patients without an event, date last seen. Local recurrences
included new nonemuscle-invasive disease. Secondary endpoints
included acute toxicity (worst grade during treatment), salvage
cystectomy rate (time from randomization to cystectomy,
censored at death), and overall survival.
Sample size
The sample size was based on demonstrating an improved toxicity
profile in the RHDVRT group. Pilot data showed that modifying
the volume of bladder irradiated with the full dose of radiation
therapy reduced RTOG grade (G)3 or G4 bladder toxicity from
43% to 23% (10). Assuming 25% of patients would not be
evaluable for toxicity at 1 year (eg, because of death), the trial set
out to randomize 480 patients to detect a reduction from 40% to
25% in RTOG G3/4 toxicity (86% power, 5% 2-sided signifi-
cance). The study also aimed to demonstrate that RHDVRTwas at
most 10% inferior to sRT in terms of 2-year LRRF rate (assuming
a 2-year rate of 50% with sRT; 70% power, 1-sided a Z 0.05).
There was clinical consensus that this noninferiority margin would
be acceptable if toxicity was significantly reduced.
Because of slow recruitment, the radiation therapy volume
randomization closed early in September 2006. Retrospective
recalculation of power showed that with 164 patients assessable for
late toxicity at 1 year the study could detect a 20%difference (40% to
20%) in RTOG G3/4 toxicity with 80% power (5% 2-sided signifi-
cance). Twohundred andnineteen randomizedpatients providedonly
56% power to detect noninferiority with a margin of 10%.
Statistical analysis
Primary analyses are by intention to treat (ITT) for efficacy
outcomes, including all randomized patients, and by treatment
received for toxicity endpoints, including all patients who received
any radiation therapy. The primary noninferiority analysis was
also performed excluding patients who did not receive their
allocated radiation therapy volume treatment or had major
protocol violations (“per-protocol” population). Noninferiority
was to be considered proven if conclusions drawn from the ITT
Fig. 1. Patientflow through the trial.RHDVRTZ reducedhigh-dosevolume radiation therapy; sRTZ standardwhole-bladder radiation therapy.
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adjusted or stratified for randomized chemotherapy group
(chemotherapy/no chemotherapy/not randomized).
Proportion of G3/4 toxicities was compared using the Mantel-
Haenszel test and distribution of toxicity grades using the Van
Elteren test. To avoid interpreting disease symptoms as treatment
side effects, late toxicity data were treated as missing from 3
months before first recurrence, second primary, or bladder cancer
death. To make some adjustment for multiple testing, a signifi-
cance level of 1% was used for toxicity endpoints at individual
timepoints, and accordingly 99% confidence intervals (CIs) are
given. Where overall cumulative toxicity rates are presented, 95%
CIs are given. Mean change in bladder capacity is calculated from
an analysis of covariance model adjusting for baseline capacity
and randomized chemotherapy group.
Time to event endpoints were analyzed by stratified logerank
test. Hazard ratios (hazard ratio <1 favoring RHDVRT) andabsolute difference were calculated from the Cox model.
The proportional hazards assumption of the Cox model, tested
using Schoenfeld residuals, held for all endpoints except
time to cystectomy. Hazard ratios adjusted for neoadjuvant
chemotherapy, age, radiation therapy dose, stage, performance
status, and tumor grade suggested robustness of the results (not
shown).
The presence of an interaction between chemotherapy and
radiation therapy volume was tested for survival and toxicity
outcomes, but the tests had low power because only 121 patients
were randomized to both comparisons. Sensitivity analyses (not
shown) were conducted as reported previously (12) and gave
similar results to the main analysis.
Time-to-event analyses were based on a database snapshot
frozen on November 2, 2011. All other analyses were based on
a database snapshot frozen on April 27, 2010. Analyses were
conducted in STATA 10 (StataCorp, College Station, TX).
Table 1 Patient and tumor characteristics at trial entry, and treatment details
Variable
sRT RHDVRT Total
n % n % n %
Total 108 100.0 111 100.0 219 100.0
Chemotherapy randomization
Chemotherapy 31 28.7 33 29.7 64 29.2
No chemotherapy 32 29.6 25 22.5 57 26.0
Elect no chemotherapy 45 41.7 53 47.7 98 44.7
Sex
Male 91 84.3 89 80.2 180 82.2
Female 17 15.7 22 19.8 39 17.8
WHO performance Status
0 57 52.8 56 50.5 113 51.6
1 42 38.9 45 40.5 87 39.7
2 9 8.3 10 9.0 19 8.7
Age at randomization (y)
Median (IQR) 75.0 (68.6, 79.9) 73.1 (65.0, 78.1) 74 (66.6, 79.0)
<60 10 9.3 13 11.7 23 10.5
60-69 23 21.3 28 25.2 51 23.3
70-79 49 45.4 50 45.0 99 45.2
80þ 26 24.1 20 18.0 46 21.0
Pathological stage, primary tumor
2 94 87.0 90 81.1 184 84.0
3a 5 4.6 7 6.3 12 5.5
3b 5 4.6 11 9.9 16 7.3
4a 3 2.8 2 1.8 5 2.3
Unknown 1 0.9 1 0.9 2 0.9
Grade, primary tumor
2 19 17.6 17 15.3 36 16.4
3 85 78.7 93 83.8 178 81.3
Unknown 4 3.7 1 0.9 5 2.3
Histologic type
TCC 106 98.1 109 98.2 215 98.2
SCC 0 0.0 1 0.9 1 0.5
TCC and SCC 1 0.9 0 0.0 1 0.5
Unknown 1 0.9 1 0.9 2 0.9
Multiple tumors
Yes* 5 4.6 4 3.6 9 4.1
If yes, no. of tumors
Median (IQR) 3 (3, 3) 2.5 (2, 3) 3 (3, 3)
Number unknown 1 2 3
No 102 94.4 106 95.5 208 95.0
Unknown 1 0.9 1 0.9 2 0.9
Tumor resection
Not resected 3 2.8 1 0.9 4 1.8
Biopsy 7 6.5 9 8.1 16 7.3
Complete resection 56 51.9 63 56.8 119 54.3
Incomplete resection 39 36.1 36 32.4 75 34.2
Resected (extent unknown) 1 0.9 1 0.9 2 0.9
Unknown 2 1.9 1 0.9 3 1.4
Residual mass after resection
Yes 38 35.2 25 22.5 63 28.8
No 65 60.2 79 71.2 144 65.8
Unknown 5 4.6 7 6.3 12 5.5
Tumor size (longest dimension, mm)
Median (IQR) 38 (20, 50) 30 (20, 40) 30 (20, 50)
Unknown 33 32 65
Neoadjuvant chemotherapy planned
Yes 26 24.1 25 22.5 51 23.3
No 82 75.9 86 77.5 168 76.7
Planned radiation therapy schedule
55 Gy/20 fx 43 39.8 35 31.5 78 35.6
64 Gy/32 fx 64 59.3 75 67.6 139 63.5
Unknown 1 0.9 1 0.9 2 0.9
Radiation therapy dose received
(continued on next page)
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Table 1 (continued )
Variable
sRT RHDVRT Total
n % n % n %
Full dose 105 97.2 106y 95.5 211 96.3
80%-<100% 1 0.9 1 0.9 2 0.9
<80% 1 0.9 1 0.9 2 0.9
None 1 0.9 3 2.7 4 1.8
Radiation therapy delays
No delay 7 d 106 98.1 107 96.4 213 97.3
Delay 7 d 2 1.9 4 3.6 6 2.7
Abbreviations: fxZ fraction; IQRZ interquartile range; RHDVRTZ reduced high-dose volume radiation therapy; SCCZ squamous cell carcinoma;
sRT Z standard whole-bladder radiation therapy; TCC Z transitional cell carcinoma; WHO Z World Health Organization.
* All ineligible for radiation therapy randomization except 1 patient in the sRT group with all tumors in same location.
y Includes 13 patients randomized to RHDVRT who received sRT.
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The trial was sponsored by the University of Birmingham and con-
ducted in accordance with the principles of Good Clinical Practice
with appropriate ethical and regulatory approvals. Central data
managementwas performedby ICR-CTSUandCancerResearchUK
Clinical Trials Unit (CRCTU), Birmingham. Central statistical
monitoring and all analyses were conducted at ICR-CTSU. The Trial
ManagementGroup (See acknowledgements)was responsible for the
day to day running of the trial. The trial was overseen by an inde-
pendent Trial Steering Committee. An Independent DataMonitoring
Committee regularly reviewed emerging safety and efficacy data.
Results
Trial participants
Between August 2001 and April 2008, 458 patients were recruited
from 45 UK centers. Of these, 219 patients (108 sRT, 111
RHDVRT) from 28 UK centers entered the radiation therapy
volume randomization, 360 patients entered the chemo-radiation
therapy randomization, including 121 who entered both. Thirteen
patients randomized to sRT versus RHDVRT were subsequently
found to be ineligible, and 13 patients randomized to RHDVRT
were treated with sRT (Fig. 1). Patient and tumor characteristics
and treatment details are given in Table 1. Full-dose radiationTable 2 Worst grade of on-treatment CTC toxicity
Acute toxicity Group
Worst CTC grad
n 0 1 2
Any toxicity sRT 120 4 (3.3) 31 (25.8) 55 (45.8
RHDVRT 95 4 (4.2) 23 (24.2) 49 (51.6
Genitourinary sRT 117 23 (19.7) 41 (35.0) 33 (28.2
RHDVRT 94 18 (19.1) 30 (31.9) 31 (33.0
Gastrointestinal sRT 117 25 (21.4) 59 (50.4) 27 (23.1
RHDVRT 94 25 (26.6) 37 (39.4) 30 (31.9
Abbreviations: CI Z confidence interval; CTC Z Common Toxicity Criter
Includes worst grade of toxicity reported across all weeks of treatment (ie, week
64 Gy/32 fx/6.5 wk. Values in parentheses are percentages.
* P value from Van Elteren (stratified Mann-Whitney) test comparing the d
y Odds ratio for G3 or G4 toxicity in RHDVRT group compared with sRT
z P value from Mantel-Haenszel test comparing the proportion of G3/4 toxtherapy was received by more than 95% of patients. Median
follow-up was 72.7 (interquartile range, 60.7 to 90.0) months.
Acute toxicity
In general, treatment was well tolerated, with G3/4 acute toxicity
seen in 49 of 215 patients (23%) and no significant difference
between radiation therapy volume groups (Table 2). The most
common on-treatment toxicity was urinary related (G3/4
frequency/nocturia: 32 patients; G3/4 dysuria: 12 patients). The
most frequent gastrointestinal toxicity was diarrhea (6 patients).
Late toxicity
There were no significant differences in the proportions of patients
reporting RTOG or LENT/SOM toxicities (Table e1, available
online) nor in time to first late G3/4 toxicity (RTOG PZ.68,
LENT/SOM, PZ.47; Fig. 2). At 1 year, G3/4 genitourinary
toxicity was reported by 2 of 54 sRT patients (3.7%) and 1 of 53
RHDVRT patients (1.9%) (PZ.45). At 2 years proportions were 1
of 42 (2.4%) and 2 of 37 (5.4%), respectively (PZ.47).
The overall cumulative G3/4 RTOG toxicity rate was 13%
(95% CI 8%, 20%) at 2 years (Fig. 2a), whereas the percentage of
patients with G3/4 toxicity at any specific point was <8%
throughout (Fig. 3) in both groups. Genitourinary toxicity was
more prevalent than gastrointestinal; the most common G3/4e
P* OR for G3/4y 99% CI Pz3 4
) 26 (21.7) 4 (3.3) .73 0.79 0.33, 1.87 .48
) 17 (17.9) 2 (2.1)
) 17 (14.5) 3 (2.6) .57 1.00 0.39, 2.60 .99
) 14 (14.9) 1 (1.1)
) 6 (5.1) 0 .85 0.38 0.04, 3.26 .23
) 2 (2.1) 0
ia; G Z grade; OR Z odds ratio. Other abbreviations as in Table 1.
s 1-4 if patient received 55 Gy/20 fx/4 wk or weeks 1-7 if patient received
istribution of grades between treatment groups.
group, adjusted for chemotherapy randomization.
icities between groups, stratified by chemotherapy randomization.
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Fig. 2. Kaplan-Meier plot of time to first grade 3/4 toxicity using
(a)RadiationTherapyOncologyGroupand (b)LateEffects ofNormal
Tissue (Subjective, Objective, Management) toxicity gradings.
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patients), and cystitis (5 patients).
The proportion of patients with G3/4 toxicity was higher on the
LENT/SOM scale (2-year actuarial rate of 46% [95% CI 37%,
54%]) than on the RTOG scale. However, the most common
LENT/SOM G3/4 toxicity was sexual dysfunction (occurring in
57 of 76 patients reporting a G3/4 LENT/SOM toxicity); it was
the only G3/4 LENT/SOM symptom in 36 patients and predated
treatment in 38 of 57 (67%), so was not a treatment-emergent
side-effect. The LENT/SOM 2-year actuarial G3/4 rate was 20%
(95% CI 14%, 28%) when excluding sexual dysfunction.
Bladder capacity
Data on change in bladder capacity are relatively incomplete, being
available for 51 and 36 patients to 1 and 2 years, respectively. In
both groups median bladder capacity was lower at 1 year than at
baseline. Adjusted mean reduction in bladder capacity in the
RHDVRT group was less than in the sRT group, but the difference
was not significant (year 1: by 30.2 mL [95% CI 91.3, 151.6],
PZ.62; year 2: by 76.0 mL [95% CI 44.9, 197.0], PZ.21).Local control
Two-year LRRF rate was, for sRT: 61% (95% CI 50%, 71%); for
RHDVRT: 64% (52%, 73%) (Fig. 4a). The 95% CI for absolute
difference in LRRF rate at 2 years excluded RHDVRT, being 10%
worse in the ITT population (RHDVRT improvement 6.4%
[7.3%, 16.8%]) but not in the per-protocol population (RHDVRT
improvement 2.6% [12.8%, 14.6%]); therefore, noninferiority
could not be formally concluded. Of 76 first locoregional recur-
rences reported, 39 were noninvasive bladder, 26 were invasive
bladder, and 10 were in pelvic nodes (1 unknown). Twenty-six
patients (11.9%) (13 sRT, 13 RHDVRT) have undergone cys-
tectomy; time to cystectomy is comparable between treatment
groups (logerank: PZ.78; 2-year rate, for sRT: 10.2% [95% CI
5.2%, 18.8%], for RHDVRT: 11.7% [6.6%, 20.1%]). Of 26
cystectomies, 23 (10 sRT, 13 RHDVRT) were for disease recur-
rence, 1 patient decided to have cystectomy before radiation therapy
(sRT), and only 2 patients (both sRT) have had salvage cystectomy
for radiation therapy side effects.
Overall survival
Five-year survival rates were 38% (95% CI 28%, 47%) for sRT
and 44% (34%, 53%) for RHDVRT (Fig. 4b).
Discussion
BC2001 is the largest randomized trial of radiation therapy in
patients with muscle-invasive bladder cancer. It concluded that
5FU and MMC chemo-radiation therapy was significantly better
than radiation therapy alone in terms of LRRF survival (hazard
ratio 0.68 [95% CI 0.48, 0.96], PZ.03) (12). We have now also
demonstrated that delivering at least 75% of dose to the unin-
volved bladder is deliverable across multiple sites without obvious
detriment to local disease control or survival (although non-
inferiority could not be formally confirmed).
We were unable to demonstrate that RHDVRT results in the
anticipated reduction in toxicity. The statistical power to demon-
strate effects in the radiation therapy volume comparison
was limited in part owing to early closure of this component of the
2  2 factorial randomization, as a result of slow accrual. Further,
the overall incidence of late RTOG toxicity was less than pre-
dicted from the single-center pilot study. This may be due to
improvements in treatment technique but more likely suggests that
either the previous study overestimated toxicity or there is
underreporting of symptoms using the RTOG scale. The incidence
of adverse events was consistent with that in a series of 4 RTOG
trials including 285 patients (17), in which throughout all follow-
up, RTOG G3 late genitourinary and gastrointestinal toxicity was
seen in 5.7% and 1.9% of patients, respectively, despite the use of
concomitant chemotherapy. The reported rate of symptoms in our
study was higher using the LENT/SOM scoredlikely a reflection
of the broader scope and multidimensionality of the scale (with
objective, subjective, and management component scores). An
alternative explanation for the lack of an effect is that the volume
reduction was not ambitious enough or that it did not spare the
relevant anatomic structures sufficiently to achieve clinically
detectable reductions in toxicity. Modeling work on a subset of
patients suggests that although the volume reduction achieved was
variable, the probability of any late bowel toxicity was propor-
tional to the overall bowel volume treated (18).
Fig. 3. Percentage of patients reporting late toxicity, by month and grade. GI Z gastrointestinal; GU Z genitourinary; LENT/SOM Z
Late Effects of Normal Tissue (Subjective, Objective, Management); RHDVRTZ reduced high-dose volume radiation therapy; RTOGZ
Radiation Therapy Oncology Group; stRT Z standard whole-bladder radiation therapy.
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series, and a significant proportion with a residual mass after
transurethral resection of bladder tumor, LRRF rates of more than
60% were achieved at 2 years. More than half of first locoregional
relapses seen were nonemuscle-invasive and thus potentially
treatable with local therapy. These results were achieved with
radiation therapy targeted at the bladder alone, with low rates of
nodal recurrence suggesting that the value of specific nodal irra-
diation is limited in this settingda view supported by the results
of a recently published randomized trial that showed no difference
in outcome between bladder-only and bladder and pelvic radiation
therapy (19). Only 26 of 219 BC2001 radiation therapy compar-
ison patients (12%) have undergone salvage cystectomy, a rate
lower than in historical series (5, 20) but similar to that seen in
more recent data (21). Some patients treated may not be fit enoughfor cystectomy, but this lower cystectomy rate could represent
case selection, better pretreatment cystoscopic resection, better
radiation therapy techniques, the use of neoadjuvant or concom-
itant chemotherapy (12), or a combination of these factors.
Our results suggest that modern radiation therapy can be used to
treat bladder cancer with a low risk of severe late toxicity, maintaining
a well-functioning bladder with normal or near-normal capacity in
most patients even when combined with synchronous chemotherapy
(11). Reduced high-dose volume radiation therapy can achieve similar
tumor control outcomes to conventional whole-bladder radiation
therapy, although to date we have not demonstrated that this approach
translates to a reduction in radiation therapy related side effects. The
introduction of image-guided treatment and better tumor localization
brings the promise of greater reductions in uninvolved bladder and
small-bowel irradiation (22) and thus further potential for reductions in
N at risk (events)
HR (95% CI) = 0.80 (0.51, 1.26)
































111 65(23) 49(6) 42(2) 35(2) 26(2) 19(0) )53=latoT(TRVDHR
108 66(23) 43(11) 34(3) 30(1) 27(1) 12(1) )14=latoT(TRs
0 12 24 36 48 60 72
Months since randomization
N at risk (events)
HR (95% CI) = 0.82 (0.58, 1.16)




















111 87(21) 70(17) 61(8) 50(7) 35(6) 27(1) )26=latoT(TRVDHR
108 88(17) 64(24) 50(14) 42(6) 35(4) 18(3) )17=latoT(TRs








Fig. 4. (a) 2Kaplan-Meier plot of time to locoregional recur-
rence. Cox model estimated absolute difference in locoregional
recurrence-free rate (95% confidence interval) at 2 years: 6.4%
(7.3%, 16.8%). First locoregional recurrence (standard whole-
bladder radiation therapy [sRT] vs reduced high-dose volume
radiation therapy [RHDVRT]) was noninvasive for 21 (19.4%) vs
18 (16.2%), invasive for 15 (13.9%) vs 11 (9.9%), in the pelvic
nodes for 5 (4.6%) vs 5 (4.5%), and unknown for one RHDVRT
patient. (b) Kaplan-Meier plot of overall survival by randomized
group. Cox model estimated absolute difference (95% confidence
interval) at 2 years: 4.7% (6.0%, 13.4%).
Volume 87  Number 2  2013 Bladder RT volume: RCT results 269side effects. We believe that this approach is valid both to reduce risks
for patients and to enable strategies of dose escalation either through
direct radiation therapy dose increases or the use of additional radio-
sensitizers. Further studies to assess such strategies are encouraged.
The overall low rates of clinically significant toxicity
combined with low rates of invasive bladder cancer relapse
confirm that (chemo)radiation therapy treatment is a valid option
for the treatment of muscle-invasive bladder cancer.References
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